FIELD: medicine.
SUBSTANCE: patient receives an effective amount of antibody and methotrexate, wherein the said antibody comprises a heavy chain variable region of SEQ ID NO: 2 and a light chain variable region of SEQ ID NO: 3, and the antibody is administered at a dose of 100 mg to 200 mg every two weeks and where the patient has been previously treated for rheumatoid arthritis by methotrexate and previously ineffectively treated for rheumatoid arthritis (RA) by TNF-α, selected from the group consisting of etanercept, infliximab, adalimumab, golimumab and/or sertolizumab pegol.
EFFECT: method allows to increase the effectiveness of rheumatoid arthritis treatment and alleviate its symptoms by specifically binding the antibody or its antigen-binding fragment to the human intreleukin-6 receptor.
10 cl, 3 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR TREATING DISEASE | 2009 |
|
RU2531548C2 |
| COMPOSITION FOR TREATING ARTHRITIS | 2009 |
|
RU2563360C2 |
| COMPOSITIONS CONTAINING ANTIBODIES TO IL6R FOR TREATMENT OF UVEITIS AND MACULAR EDEMA AND METHODS OF THEIR USE | 2016 |
|
RU2747193C2 |
| GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS | 2014 |
|
RU2714919C2 |
| IL-6 RECEPTOR ANTIBODY FOR TREATING JUVENILE IDIOPATHIC ARTHRITIS | 2020 |
|
RU2822089C2 |
| METHODS OF TREATING RHEUMATOID ARTHRITIS USING IL-17 ANTAGONISTS | 2011 |
|
RU2582937C2 |
| METHOD OF TREATING JOINT INJURIES | 2006 |
|
RU2457860C2 |
| TREATMENT OF PROLIFERATIVE ARTHRITIS | 2003 |
|
RU2322238C2 |
| USE OF IL-17 ANTAGONISTS FOR INHIBITION OF STRUCTURAL DAMAGE PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS | 2015 |
|
RU2697383C2 |
| METHOD FOR PREDICTING EFFECTIVENESS OF TREATMENT OF RHEUMATOID ARTHRITIS WITH DRUG OLOKIZUMAB USING EPIGENETIC MARKERS | 2020 |
|
RU2749248C1 |
